Neuroimaging of rapid eye movement sleep behavior disorder: Transcranial ultrasound, single-photon emission computed tomography, and positron emission tomography scan data

Sleep Medicine

Volumn 14, Issue 8, 2013, Pages 739-743

  Miyamoto, Masayuki ^a   Miyamoto, Tomoyuki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Dementia with Lewy bodies (DLB); Multiple system atrophy (MSA); Parkinson disease (PD); Positron emission tomography (PET); REM sleep behavior disorder (RBD); Single photon emission computed tomography (SPECT); Transcranial ultrasound sonography (TCS)

Indexed keywords

6 FLUORO META TYROSINE F 18; 6 FLUORODOPA F 18; IOLOPRIDE I 123; IOMETOPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

B SCAN; CLINICAL FEATURE; CLINICAL RESEARCH; CORRELATION ANALYSIS; DIFFUSE LEWY BODY DISEASE; DISEASE COURSE; EARLY DIAGNOSIS; ECHOGRAPHY; HUMAN; PARASOMNIA; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SHY DRAGER SYNDROME; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UNIFIED PARKINSON DISEASE RATING SCALE;

DEMENTIA WITH LEWY BODIES (DLB); MULTIPLE SYSTEM ATROPHY (MSA); PARKINSON DISEASE (PD); POSITRON EMISSION TOMOGRAPHY (PET); REM SLEEP BEHAVIOR DISORDER (RBD); SINGLE-PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT); TRANSCRANIAL ULTRASOUND SONOGRAPHY (TCS);

HUMANS; POSITRON-EMISSION TOMOGRAPHY; REM SLEEP BEHAVIOR DISORDER; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; ULTRASONOGRAPHY, DOPPLER, TRANSCRANIAL;

EID: 84881543414     PISSN: 13899457     EISSN: 18785506     Source Type: Journal    
DOI: 10.1016/j.sleep.2013.03.004     Document Type: Review

References (43)

1. Schenck C.H., Mahowald M.W. REM sleep behavior disorder: clinical, developmental, and neuroscience perspectives 16years after its formal identification in sleep. Sleep 2002, 25:120-138.
2. Gagnon J.F., Postuma R., Mazza S., Doyon J., Montplaisir J. Rapid-eye-movement. sleep behavior disorder and neurodegenerative diseases. Lancet Neurol 2006, 5:424-432.
3. Postuma R.B., Lang A.E., Massicotte-Marquez J., Montplaisir J. Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology 2006, 66:845-851.
4. Postuma R.B., Gagnon J.F., Vendette M., Montplaisir J.Y. Markers of neurodegeneration in idiopathic rapid eye movement sleep behaviour disorder and Parkinson's disease. Brain 2009, 132:3298-3307.
5. Maetzler W., Liepelt I., Berg D. Progression of Parkinson's disease in the clinical phase: potential markers. Lancet Neurol 2009, 8:1158-1171.
6. Becker G., Müller A., Braune S., Büttner T., Benecke R., Greulich W., et al. Early diagnosis of Parkinson's disease. J Neurol 2002, 249(Suppl. 3). III/40-8.
7. 123I-MIBG scintigraphy in idiopathic REM sleep behavior disorder. Neurology 2006, 67:2236-2238.
8. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 2008, 31:717-723.
9. Schenck C.H., Bundlie S.R., Mahowald M.W. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996, 46:388-393.
10. Schenck C.H., Boeve B.F., Mahowald M.W. Delayed emergence of a parkinsonian disorder or dementia in 81% of older males initially diagnosed with idiopathic REM sleep behavior disorder (RBD): 16year update on a previously reported series. Sleep Med 2013, 14:744-748.
11. Boeve B.F., Dickson D.W., Olson E.J., Shepard J.W., Silber M.H., Ferman T.J., et al. Insights into REM sleep behavior disorder pathophysiology in brainstem-predominant Lewy body disease. Sleep Med 2007, 8:60-64.
12. Boeve B.F., Silber M.H., Saper C.B., Ferman T.J., Dickson D.W., Parisi J.E., et al. Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease. Brain 2007, 130:2770-2788.
13. Berg D., Godau J., Walter U. Transcranial sonography in movement disorders. Lancet Neurol 2008, 7:1044-1055.
14. Becker G., Seufert J., Bogdahn U., Reichmann H., Reiners K. Degeneration of the substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology 1995, 45:182-184.
15. 123]I-IPT and single-photon emission tomography. Eur J Nucl Med 1997, 24:415-421.
16. Seibyl J.P., Marek K., Sheff K., Zoghbi S., Baldwin R.M., Charney D.S., et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998, 39:1500-1508.
17. Berg D., Becker G., Zeiler B., Tucha O., Hofmann E., Preier M., et al. Vulnerability of the nigrostriatal system as detected by transcranial ultrasound. Neurology 1999, 53:1026-1031.
18. Berg D., Roggendorf W., Schröder U., Klein R., Tatschner T., Benz P., et al. Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. Arch Neurol 2002, 59:999-1005.
19. 123I] FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. Synapse 2001, 39:101-108.
20. Weise D., Lorenz R., Schliesser M., Schirbel A., Reiners K., Classen J. Substantia nigra echogenicity: a structual correlate of functional impairment of the dopaminergic striatal projection in Parkinson's disease. Mov Disord 2009, 24:1669-1675.
21. Behnke S., Schroeder U., Dillmann U., Buchholz H.G., Schreckenberger M., Fuss G., et al. Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET. Neuroimage 2009, 47:1237-1243.
22. 123I] FP-CIT SPECT disclose complementary aspects of Parkinson's disease. Brain 2006, 129:1188-1193.
23. 123I-FP-CIT SPECT in Parkinson's disease and essential tremor. Mov Disord 2008, 23:405-410.
24. Walter U., Klein C., Hilker R., Benecke R., Pramstaller P.P., Dressler D. Brain parenchyma sonography detects preclinical parkinsonism. Mov Disord 2004, 19:1445-1449.
25. Berg D., Merz B., Reiners K., Naumann M., Becker G. Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease. Mov Disord 2005, 20:383-385.
26. Berg D., Seppi K., Liepelt I., Schweitzer K., Wollenweber F., Wolf B., et al. Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly. Mov Disord 2010, 25:1464-1469.
27. Unger M.M., Möller J.C., Stiasny-Kolster K., Mankel K., Berg D., Walter U., et al. Assessment of idiopathic rapid-eye-movement sleep behavior disorder by transcranial sonography, olfactory function test, and FP-CIT-SPECT. Mov Disord 2008, 23:596-599.
28. Stockner H., Iranzo A., Seppi K., Serradell M., Gschliesser V., Sojer M., et al. Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder. Mov Disord 2009, 24:1906-1909.
29. Iwanami M., Miyamoto T., Miyamoto M., Hirata K., Takada E. Relevance of substantia nigra hyperechogenicity and reduced odor identification in idiopathic REM sleep behavior disorder. Sleep Med 2010, 11:361-365.
30. Shin H.Y., Joo E.Y., Kim S.T., Dhong H.J., Cho J.W. Comparison study of olfactory function and substantia nigra hyperechogenicity in idiopathic REM sleep behavior disorder, Parkinson's disease and normal control. Neurol Sci 2012, http://dx.doi.org/10.1007/s10072-012-1164-0 [published online ahead of print July 28, 2012].
31. Mahlknecht P., Stockner H., Nocker M., Kiechl S., Willeit J., Scherfler C., et al. A follow-up study of substantia nigra echogenicity in healthy adults. Mov Disord 2012, 27:1192-1194.
32. Miyamoto M., Miyamoto T., Iwanami M., Muramatsu S., Asari S., Nakano I., et al. Preclinical substantia nigra dysfunction in rapid eye movement sleep behavior disorder. Sleep Med 2012, 13:102-106.
33. 18F]fluoro-l-m-tyrosine uptake in the striatum in Parkinson's disease. BMC Neurol 2011, 11:35.
34. Iranzo A., Lomeña F., Stockner H., Valldeoriola F., Vilaseca I., Salamero M. Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2010, 9:1070-1077. [corrected][published correction appears in Lancet Neurol 2010;9:1045][published online ahead of print September 16, 2010][corrected].
35. Siderowf A., Lang A.E. Premotor Parkinson's disease: concepts and definitions. Mov Disord 2012, 27:608-616.
36. Albin R.L., Koeppe R.A., Chervin R.D., Consens F.B., Wernette K., Frey K.A., et al. Decreased striatal dopaminergic innervation in REM sleep behavior disorder. Neurology 2000, 55:1410-1420.
37. Eisensehr I., Linke R., Tatsch K., Kharraz B., Gildehaus J.F., Wetter C.T., et al. Increased muscle activity during rapid eyemovement sleep correlates with decrease of striatal presynaptic dopamine transporters. IPT and IBZM SPECT imaging in subclinical and clinically manifest idiopathic REM sleep behavior disorder, Parkinson's disease, and controls. Sleep 2003, 26:507-512.
38. Kim Y.K., Yoon I.Y., Kim J.M., Jeong S.H., Kim K.W., Shin Y.K., et al. The implication of nigrostriatal dopaminergic degeneration in the pathogenesis of REM sleep behaviour disorder. Eur J Neurol 2010, 17:487-492.
39. Miyamoto T., Orimo S., Miyamoto M., Hirata K., Adachi T., Hattori R., et al. Follow-up PET studies in case of idiopathic REM sleep behavior disorder. Sleep Med 2010, 11:100-101.
40. 18F] CFT PET. Synapse 2003, 48:109-115.
41. Iranzo A., Valldeoriola F., Lomeña F., Molinuevo J.L., Serradell M., Salamero M. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol 2011, 10:797-805.
42. 18F] fluoro-l-dopa PET study. Mov Disord 2001, 16:608-615.
43. Miyamoto T, Miyamoto M, Hirata K. Preclinical dopaminergic dysfunction in rapid eye movement sleep disorder. Sleep Biol Rhythms 2013(Suppl.1). http://dx.doi.org/10.1111/j.1479-8425.2012.00554.x.